UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 398

Sortiert nach

Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking

Leukemia, 2020-10, Vol.34 (10), p.2660-2672

2020

Link zum Volltext

Verfügbarkeit prüfen

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Nature genetics, 2010-08, Vol.42 (8), p.722-726

2010

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2428-2436

2013

Link zum Volltext

Verfügbarkeit prüfen

HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions

Leukemia, 2021-11, Vol.35 (11), p.3040-3043

2021

Link zum Volltext

Verfügbarkeit prüfen

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Nature genetics, 2009-04, Vol.41 (4), p.446-449

2009

Link zum Volltext

Verfügbarkeit prüfen

EZH2 mutational status predicts poor survival in myelofibrosis

Blood, 2011-11, Vol.118 (19), p.5227-5234

2011

Link zum Volltext

Verfügbarkeit prüfen

Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable

International journal of hematology, 2015-03, Vol.101 (3), p.229-242

2015

Link zum Volltext

Verfügbarkeit prüfen

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Blood, 2012-02, Vol.119 (5), p.1208-1213

2012

Link zum Volltext

Verfügbarkeit prüfen

Aberrations of EZH2 in Cancer

Clinical cancer research, 2011-05, Vol.17 (9), p.2613-2618

2011

Link zum Volltext

Verfügbarkeit prüfen

Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia

Leukemia, 2020-09, Vol.34 (9), p.2279-2284

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations

British journal of haematology, 2013-01, Vol.160 (1), p.25-34

2013

Link zum Volltext

Verfügbarkeit prüfen

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

BMC cancer, 2022-09, Vol.22 (1), p.1013-15, Article 1013

2022

Link zum Volltext

Verfügbarkeit prüfen

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes

Annals of hematology, 2015-02, Vol.94 (2), p.233-238

2015

Link zum Volltext

Verfügbarkeit prüfen

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis

Annals of hematology, 2014-01, Vol.93 (1), p.81-88

2014

Link zum Volltext

Verfügbarkeit prüfen

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Blood, 2011-08, Vol.118 (5), p.1208-1215

2011

Link zum Volltext

Verfügbarkeit prüfen

Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease

Leukemia, 2022-02, Vol.36 (2), p.507-515

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study

British journal of haematology, 2008-12, Vol.143 (5), p.707-715

2008

Link zum Volltext

Verfügbarkeit prüfen

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression

British journal of haematology, 2013-10, Vol.163 (2), p.235-239

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 398

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(383)
Mit Volltextzugriff
(358)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(308)
Humans
(287)
Life Sciences & Biomedicine
(286)
Hematology
(174)
Male
(143)
Biological And Medical Sciences
(127)
Female
(127)
Medical Sciences
(113)
Middle Aged
(111)
Aged
(96)
Adult
(92)
Oncology
(91)
Hematologic And Hematopoietic Diseases
(73)
Mutation
(71)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(67)
Myeloproliferative Disorders - Genetics
(48)
Aged, 80 And Over
(44)
Oncogene Proteins, Fusion - Genetics
(42)
Translocation, Genetic
(41)
Base Sequence
(38)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(69)
British Journal Of Haematology
(39)
Haematologica
(27)
Leukemia
(20)
Genes Chromosomes & Cancer
(14)
Monthly Notices Of The Royal Astronomical Society
(13)
Acta Haematologica
(11)
Annals Of Hematology
(9)
Journal Of Clinical Oncology
(9)
Leukemia Research
(9)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

EZH2 mutational status predicts poor survival in myelofibrosis

Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Aberrations of EZH2 in Cancer

Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia

TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression

Suchergebnisse filtern